Crinetics Pharmaceuticals, Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

For the quarterly period ended March 31, 2026

For the transition period from ______ to

Commission File Number:001-38583

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code:(858)450-6464

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No☑

As of April 23, 2026, the registrant had 105,440,208 shares of common stock ($0.001 per share par value) outstanding.

GLOSSARY OF DEFINED TERMS

Unless expressly indicated or the context requires otherwise, the terms “Crinetics,” “Company,” “we,” “us,” and “our,” in this Quarterly Report on Form 10-Q (this “Report”) refer to Crinetics Pharmaceuticals, Inc., a Delaware corporation, and, where appropriate, its wholly-owned subsidiaries. We also have used several other terms in this Report, most of which are explained or defined below.

“2018 Plan”means our 2018 Incentive Award Plan.

“2021 Inducement Plan”means our 2021 Employment Inducement Incentive Award Plan.

“2022 Lease”means our operating lease for our headquarters in San Diego, California.

“2024 Sales Agreement”means the Sales Agreement entered into by and between Crinetics and the Sales Agents on June 21, 2024.

“ADCS”means ACTH-Dependent Cushing’s Syndrome.

“ANVISA” means Agência Nacional de Vigilância Sanitária, or the Brazilian Health Regulatory Agency.

“ASC” means Accounting Standards Codification.

“ASU”means Accounting Standards Update.

“ATM”means at-the-market.

“CAH” means congenital adrenal hyperplasia.

“CHMP” means the Committee for Medicinal Products for Human Use.

“CODM” means chief operating decision maker.

“CROs” means contract research organizations.

“CS” means carcinoid syndrome.

“EC” means the European Commission.

“EMA” means the European Medicines Agency.

“Enrollment Form” means an official document containing both HCP and patient consent, submitted to CrinetiCARE or specialty pharmacies to initiate a patient on PALSONIFY. Enrollment forms metric also includes direct dispenses from pituitary treatment centers or community practices to patients.

“ESPP” means our 2018 Employee Stock Purchase Plan.

“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended.

“FASB” means the Financial Accounting Standards Board.

“FDA” means the U.S. Food and Drug Administration.

“FY 2025 Form 10-K” means our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 26, 2026.

“GPCRs”means G-protein coupled receptors.

“HCP”means healthcare professionals.

“Lilly”means Eli Lilly and Company.

“Loyal”means Cellular Longevity Inc., doing business as Loyal.

“MAA” means Marketing Authorization Application.

“NETs” means neuroendocrine tumors.

“OLE” means open-label extension.

“PBEs” means public business entities.

“Quickstart” means a program that provides eligible patients with a temporary supply of PALSONIFY at no cost while insurance coverage is pending or under appeal. This program is designed to ensure continuity of care during delays in insurance coverage determination.

i

“Radionetics” means Radionetics Oncology, Inc.

“Radionetics License” means the collaboration and license agreement entered into with Radionetics in October 2021.

“Radionetics Warrant” means the warrant issued to the Company by Radionetics pursuant to the Radionetics License.

“RSUs”means restricted stock units.

“Sales Agents”means SVB Leerink LLC and Cantor Fitzgerald & Co.

“SEC”means the U.S. Securities and Exchange Commission.

“SKK” means Sanwa Kagaku Kenkyusho Co., Ltd.

“SKK License” means the license agreement entered into with SKK on February 25, 2022.

“SST2” means the somatostatin receptor type 2.

“SEC” means the Securities and Exchange Commission.

“U.S.” means United States.

“U.S. GAAP” means U.S. Generally Accepted Accounting Principles.

“VIE” means variable interest entity.

ii